Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood - a longitudinal analysis of long-term follow-up of a randomized controlled trial by Best, K.P. et al.
ORIGINAL RESEARCH Open Access
Prenatal omega-3 LCPUFA and symptoms
of allergic disease and sensitization
throughout early childhood – a
longitudinal analysis of long-term follow-up
of a randomized controlled trial
K. P. Best1,2,7* , T. R. Sullivan3, D. J. Palmer4,5, M. Gold2, J. Martin6, D. Kennedy2,6 and M. Makrides1,2
Abstract
Background: Randomized controlled trials of prenatal omega (ω-3) long chain polyunsaturated fatty acid (LCPUFA)
supplementation are suggestive of some protective effects on allergic sensitization and symptoms of allergic
disease in childhood. Due to the nature of the atopic march, investigation of any effects of this prenatal
intervention may be most informative when consistently assessed longitudinally during childhood.
Methods: Follow-up of children (n= 706) with familial risk of allergy from the Docosahexaenoic Acid to Optimize Mother
Infant Outcome (DOMInO) trial. The intervention group received fish oil capsules (900 mg of ω-3 LCPUFA) daily from
<21 weeks’ gestation until birth; the control group received vegetable oil capsules without ω-3 LCPUFA. This new
longitudinal analysis reports previously unpublished data collected at 1 and 3 years of age. The allergic disease symptom data
at 1, 3 and 6 years of age were consistently reported by parents using the "International Study of Asthma and Allergies in
Childhood" (ISAAC) questionnaire. Sensitization was determined by skin prick test to age specific, common allergen extracts.
Results: Changes over time in symptoms of allergic disease with sensitization (IgE-mediated) and sensitization did not differ
between the groups; interaction p= 0.49, p= 0.10, respectively. Averaged across the 1, 3 and 6-year assessments, there were
no significant effects of prenatal ω-3 LCPUFA supplementation on IgE-mediated allergic disease symptoms (adjusted relative
risk 0.88 (95% CI 0.69, 1.12), p=0.29) or sensitization (adjusted relative risk 0.97 (95% CI 0.82, 1.15), p=0.76). Sensitization
patterns to common allergens were consistent with the atopic march, with egg sensitization at 1 year strongly associated
with house dust mite sensitization at 6 years, (p< 0.0001).
Discussion: Although there is some evidence to suggest that maternal supplementation with 900mg ω-3 LCPUFA has a
protective effect on early symptoms of allergic disease and sensitization in the offspring, we did not observe any
differences in the progression of disease over time in this longitudinal analysis. Further investigation into the dose and
timing of ω-3 LCPUFA supplementation, including long-term follow up of children using consistent outcome reporting, is
essential to determine whether this intervention may be of benefit as a primary prevention strategy for allergic disease.
Conclusion: Maternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated
allergic disease symptoms or sensitization throughout childhood from 1 to 6 years.
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Background
The relentless increase in the worldwide prevalence of aller-
gic disease has heightened the need for primary prevention
[1]. Although the rise is unlikely to be due to a single factor,
there is consensus that the cause may be due to our chan-
ging lifestyle, including diet and environment. Diet in indus-
trialized countries has changed dramatically over the last
50 years, particularly in the balance of fats consumed. Opti-
mal health requires a relative balance of omega-3 (ω-3) and
omega-6 (ω-6) fatty acids, however studies report that some
‘Western’ diets contain an overabundance of ω-6 fats at the
expense of ω-3 fats [2]. The impact of this change may carry
heightened importance for the prenatal period, when the
developing fetus is reliant solely on the maternal diet.
There is increasing evidence to support modulation of
fetal immune development following prenatal ω-3
LCPUFA supplementation [3–5]. Diets high in ω-3
LCPUFA (from fish and fish oils) increase cell membrane
docosahexaenoic acid (DHA; 22:6 ω-3) and eicosapenta-
enoic acid (EPA; 20:5 ω-3), competing with the synthesis
of inflammatory arachidonic acid (AA, 20:4, ω − 6), which
results in a reduction in prostaglandin E synthesis and in-
hibition of cytokine and immunoglobulin E (IgE) produc-
tion associated with allergies [6].
Cohort studies have consistently reported that increased
ω-3 LCPUFA consumption during pregnancy may reduce
the risk of atopic eczema, asthma and sensitization to
house dust mite (HDM) [7], although it is difficult to infer
a causal link from these studies given the potential for re-
sidual confounding from environmental factors. Published
reviews assessing the effect of n–3 LCPUFAs in the pri-
mary prevention of allergic disease have been conducted
[7–13]. However, not all are systematic and most pool re-
sults from varying supplementation periods including preg-
nancy, pregnancy and lactation or the lactation period
only, thus increasing the variability of results and poten-
tially diluting any causal effect of the intervention. Evidence
from randomized controlled trials (RCTs) of prenatal sup-
plementation with ω-3 LCPUFA report consistent protect-
ive effects on the risk of IgE mediated eczema [14, 15] and
sensitization to egg [14–17] at 1 year of age. However, only
one of these trials extended follow-up to school age,
reporting a reduction in sensitization to HDM only and no
effect on parent reported symptoms of IgE-mediated aller-
gic disease at 6 years of age [18]. Two trials from Denmark
that have conducted follow up beyond infancy report a
protective effect of prenatal ω-3 LCPUFA supplementation
(predominantly as EPA) on cumulative wheeze (independ-
ent of sensitization) at 3–5 years of age [19] and atopic
asthma at 16 and 24 years of age [20, 21].
Longitudinal analyses have long been recognized as an
important tool for obtaining high quality evidence about the
determinants of development across the lifespan [22]. How-
ever, RCT’s of ω-3 LCPUFA supplementation to date, have
only reported allergic disease outcomes from distinct
follow-up time points, often with inconsistent outcomes
which prevent any analysis to investigate change over time.
Given the progressive and heterogenous nature of allergic
disease, we aim to investigate if prenatal ω-3 LCPUFA sup-
plementation will modify the course of allergen sensitization
or allergic disease symptoms over time (from 1 to 6 years of
age). Previously published 1 and 3-year of age allergic dis-
ease outcomes from our RCT were based on physician
examination and diagnosis of allergic disease, [17, 23]
whereas the 6-year results were based on parent reported
symptoms using the ‘International Study of Asthma and
Allergies in Childhood’ (ISAAC) questionnaire [18]. In this
new analysis we have combined previously unpublished
ISAAC data collected at 1 and 3 years with 6-year data to
permit investigation of the effects of prenatal ω-3 LCPUFA
supplementation on the progression of consistently parent
reported allergic disease symptoms.
Methods
Description of participants
This study is a longitudinal synthesis of data obtained at
the 1, 3 and 6 year follow up assessment of children at
hereditary risk of allergic disease, born to mothers en-
rolled in the multi-center, double-blind, DOMInO (DHA
to Optimize Mother Infant Outcome) RCT [24]. The
methods of the DOMInO Trial have been published previ-
ously [24]. Briefly, women < 21 weeks’ gestation with a
singleton pregnancy were randomly allocated to either
treatment or control group through a computer driven
telephone randomization service stratified by center and
parity (first birth versus subsequent births). Women were
asked to consume capsules containing either fish oil con-
centrate, providing ~ 800 mg/day DHA and 100 mg/day
EPA or control capsules containing a blend of three
non-genetically modified oils (rapeseed, sunflower, and
palm) in equal proportions and designed to match the
polyunsaturated, monounsaturated, and saturated fatty
acid profile of the average Australian diet [25] (Incromega
500 TG, Croda Chemicals, East Yorkshire, England). The
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supplementation period commenced at enrolment
(< 21 weeks’ gestation) until delivery. All capsules were
similar in size, shape, and color, and neither the women
nor research staff were aware of the treatment allocated.
Women reported their adherence to supplementation at
telephone calls at 28 and 36 weeks’ gestation and the con-
centration of individual LCPUFA in plasma phospholipids
from cord blood was assessed as an independent bio-
marker of compliance. Pregnant women enrolled in the
DOMInO Trial from two South Australian Centers
(Flinders Medical Center and the Women’s and Children’s
Hospital) were invited to participate in an early childhood
allergy follow up if their unborn child had a familial his-
tory of allergic disease (mother, father, or sibling with a
self-reported history of medically diagnosed eczema,
asthma, or hay fever). Written informed consent was
sought (prior to birth) for the offspring to take part in an
allergy assessment at 1 and 3 years of age (n = 706). Fam-
ilies of children who consented to the 1 and 3 years of age
allergy follow up were contacted again when the child
turned 5 years and 9 months and invited to take part in
the 6-year of age follow up (n = 668), Fig. 1. Results of the
early childhood allergy follow up involving physician
examination to determine allergic disease outcomes at 1
and 3 years of age, and a subsequent school age follow up
study at 6 years of age using ISAAC questionnaire to de-
termine allergic disease symptoms have been previously
published [17, 18, 23]. Approval for all allergy follow up
was granted by the Human Research Ethics Committees
of the Women’s and Children’s Hospital and the Southern
Adelaide Health Service, Adelaide, and trials were regis-
tered on the Australian New Zealand Clinical Trials Regis-
try (ACTRN); DOMInO trial ACTRN12605000569606,
early childhood allergy follow up ACTRN12610000735055
and 6-year allergy follow up ACTRN12615000498594.
Assessment of allergic disease
Early childhood follow-up appointments at 1 and 3 years
of age consisted of physician assessment of allergic disease
and interviewer administered parent reported symptom
questionnaires using the International study of Asthma
and Allergy in Childhood (ISAAC) questionnaire [17, 23].
Additional funding was obtained to conduct a 6 year
follow up which did not include a physician assessment.
Children attended a clinic appointment and parents were
interviewed using ISAAC questionnaires to determine
allergic disease symptoms [18]. Allergic disease outcomes
included in this longitudinal analysis are based on the par-
ent reported symptoms ascertained via ISAAC question-
naires at 1, 3 and 6 years of age. History of symptoms
related to the previous 12-month period and included ec-
zema and wheeze at 1, 3 and 6 years, and rhinitis and
rhino-conjunctivitis at 3 and 6 years. Eczema was defined
as the history of an itchy rash distributed to the facial, flex-
ural or extensor surface of the skin. Wheeze was defined as
a history of wheezing or whistling in the chest. Rhinitis was
defined as a history of sneezing or a runny or blocked nose
when there have not been symptoms to suggest an upper
Fig. 1 Flow of participants consented to the nested allergy follow-up of the DOMInO trial
Best et al. World Allergy Organization Journal  (2018) 11:10 Page 3 of 11
respiratory tract infection. Rhino-conjunctivitis was defined
as a history of sneezing or a runny or blocked nose accom-
panied by itchy-watery eyes when there have not been
symptoms to suggest an upper respiratory tract infection
[26]. All ISAAC questionnaires were administered consist-
ently at each time point in accordance with guidelines de-
tailed in the ISAAC user manual [27].
Assessment of sensitization
Sensitization was assessed at 1, 3 and 6 years by skin prick
test (SPT) to common, age specific allergens. One of five ex-
perienced research nurses who were blinded to treatment
group allocation and specifically trained in pediatric skin
prick testing performed the SPTs. SPT’s were performed in
a standardized manner and nurses underwent quality assur-
ance reviews every 6 months with one of the investigators.
Sensitization was defined as a positive reaction to at least
one of the allergen extracts assessed. As per the Australasian
Society of Clinical Immunology and Allergy (ASCIA) man-
ual, a test was considered positive if the mean of the hori-
zontal and perpendicular weal diameters was ≥3 mm than
that of the negative control site at 15 min [28]. Food allergen
extracts were selected according to common foods per age
group and aero-allergens were selected based on typical en-
vironmental allergens in the geographical area of South
Australia, see Table 1. Glycerine and histamine (10 mg/mL)
were used as negative and positive controls at each time
point. Allergen extracts that were assessed at 2 or more time
points were included in the longitudinal analysis.
Statistical analysis
Longitudinal outcomes were compared between groups
using log binomial generalized estimating equations. An
independence working correlation matrix was used in
each of these models to adjust for the dependence within
participants due to repeated measurements over time. In
the models the effects of treatment group, time (categor-
ical) and the interaction between treatment group and
time were assessed. Adjustment was also made for the
stratification variables parity (first birth vs. subsequent
birth) and center, as well as the prognostic variables gen-
der and maternal history of allergic disease. Where the
interaction term between group and time was not statisti-
cally significant, a second model excluding the interaction
term was fitted to estimate the effect of treatment over all
time points. The effect of treatment, whether at an indi-
vidual time point or across all time points, was described
using relative risks and 95% confidence intervals. All ana-
lyses were performed using SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA).
Results
Sample and participant flow
Enrolment to the nested early childhood allergy follow
up began in 2006. A total of 706 offspring were con-
sented between 2006 and 2008 to take part. Of these,
666 (94.3%) infants completed allergy symptom ques-
tionnaires and skin prick testing at 1 year of age and 638
(90.3%) at 3 years of age. In 2012, following the exclu-
sion of deaths and withdrawals from the early childhood
sample, a total of 668 children remained eligible to par-
ticipate in the 6-year allergy follow up. Six-year assess-
ments were completed in August 2014 with a total 603/
668 (90.0%) allergy symptom questionnaires completed
and 485/668 (73.0%) children undergoing SPT to deter-
mine sensitization, Fig. 1.
Baseline characteristics and compliance
The baseline enrolment characteristics of the women
and their offspring who were consented to participate in
allergy follow-up have been previously described [17] In
brief, mean maternal age at trial entry was 29.6 years
(SD 5.7 years) and 13.0% of the participating mothers
smoked during pregnancy. All unborn children had at
least one first-degree relative with a history of medically
diagnosed allergic disease; 70% had a history of maternal
allergic disease, 54.0% paternal disease and 29.0% allergic
disease in both parents. A total of 39.8% were first born
children and 47.7% were males. There were no import-
ant differences in baseline characteristics at study enrol-
ment between the intervention and control groups.
Compliance with the intervention was high, with
77.0% of mothers in the ω-3 LCPUFA group and 80.0%
of mothers in the control group reporting that they had
missed zero to three capsules a week (from a total of 21
capsules per week) at 28 weeks’ gestation. DHA concen-
tration in the plasma phospholipids of cord blood from
Table 1 Allergen extracts assessed by SPT at 1, 3 and 6 years
1 year 3 years 6 years
Cow’s milk – –






Perennial rye grass Perennial rye grass Perennial rye grass
Olive tree pollen Olive tree pollen Olive tree pollen
Alternaria tenuis Alternaria tenuis Alternaria tenuis
Cat Cat Cat
– – Dog
D. pteronyssinus D. pteronyssinus D. pteronyssinus
– D. farinae D. farinae
Abbreviations: D. pteronyssinus Dermatophagoides pteronyssinus, D. farinae
Dermatophagoides farinae
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infants in the high-DHA group was greater than control
(DHA 3.54 to 13.68% vs control 3.51 to 11.21%; median,
7.2% vs 6.1% total phospholipid fatty acids, P < 0.001).
Fewer than 2.0% of mothers in each group chose not to
take any capsules.
Allergic disease symptoms
The prevalence of ‘any’ allergic disease symptoms (irre-
spective of sensitization) increased from 17.5% at 1 year
of age to 49.3% at 6 years of age. Allergic disease symp-
toms with evidence of sensitization were reported less
often but with a similar increase in prevalence over time
from 5.3% at 1 year of age to 29.0% at 6 years of age.
Longitudinal analysis found no evidence that the differ-
ence between the ω-3 LCPUFA and control groups in
the risk of ‘any’ IgE mediated allergic disease or ‘individ-
ual IgE mediated allergic disease symptoms (eczema,
rhinitis, rhino-conjunctivitis or wheeze)’ changed over
time (group by time interaction p-values > 0.05). After
excluding the group by time interaction effect from the
models, there were no significant differences between
the prenatal ω-3 LCPUFA supplementation and control
groups in the risk of ‘any’ IgE-mediated allergic disease
or individual IgE-mediated allergic disease symptoms
Table 2 Longitudinal analysis of allergic disease symptoms with sensitization at 1, 3 and 6 years of age






































































































































































For ω-3 LCPUFA and control groups, data are number of subjects (percentage)
Rhinitis & Rhino-conjunctivitis symptoms not assessed at 1 year
Abbreviations: CI confidence interval, ω-3 LCPUFA long chain polyunsaturated fatty acid, RR relative risk
a bAdjusted for enrolling centre, parity, child sex and maternal history of allergic disease
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(eczema, rhinitis, rhino-conjunctivitis, and wheeze) with
sensitization across all years (group p-values > 0.05),
Table 2. Although a difference between groups was
observed at 1 year of age (aRR 0.51, 95% CI 0.28 to 0.92,
P = 0.03), the effect did not persist at 3 and 6 years, such
that overall the longitudinal analysis did not provide any
evidence of an effect of ω-3 LCPUFA supplementation.
Analysis of sensitization to individual allergen extracts
The prevalence of ‘any sensitization’ (≥1 positive SPT re-
action to any allergen extract) increased with the age of
the child from 17.0% at 1 year of age to 50.0% at 6 years
of age. Sensitization outcomes were included in the lon-
gitudinal analysis if the allergen extract was assessed at
two or more time-points. Sensitization results for indi-
vidual allergen extracts at 1, 3 and 6 years are presented
in Figs. 2, 3, 4, 5, 6 and 7. Longitudinal analysis found
little evidence that the effect of treatment on ‘any
sensitization’ or sensitization to individual allergen ex-
tracts changed over time (group by time interaction
P-values > 0.05). After excluding interaction effects,
there were no significant differences between groups in
the risk of ‘any sensitization’ or ‘sensitization to individ-
ual allergen extracts’ across all years (group p-values >
0.05). However, the direction of effect was similar for
many of the extracts across all years. The relative risk as-
sociated with ω-3 LCPUFA supplementation ranged be-
tween 0.50 and 0.70 for hen’s egg, peanut, cashew and
D. farinae, Table 3.
Hen’s egg and HDM sensitization associations
Although there was no evidence for a change in risk across
all years, ω-3 LCPUFA supplementation was observed to de-
crease the risk of hen’s egg sensitization at 1 year and HDM
sensitization at 6 years, Table 3. Based on these results, in
exploratory analyses we investigated the relationship be-
tween these two sensitization measures. Overall, the risk of
HDM sensitization at 6 years of age was 40.3% in children
with egg sensitization at 1 year of age compared to 13.2% in
children without egg sensitization (P < 0.0001), with the as-
sociation more pronounced in the ω-3 LCPUFA group (in-
crease from 9.7 to 37.5%) than in the control group (17.3 to
42.1%). Given the strong association between sensitization
outcomes, a mediation analysis was undertaken to test
whether the effect of treatment on HDM sensitization at
6 years of age was mediated through earlier effects on egg
sensitization. Since adjustment for egg sensitization at 1 year
had little impact on the estimated effect of treatment on
HDM sensitization at 6 years (relative risk changing from
0.62 without adjustment, to 0.69 with adjustment), it seems
that most of the effect of treatment on HDM sensitization
was unrelated to earlier effects on egg sensitization.
Discussion
This longitudinal analysis of our nested allergy cohort from
the DOMInO Trial [24] was designed to determine the ef-
fect of prenatal ω-3 LCPUFA supplementation on parent
reported allergic disease symptoms and sensitization over
time. Our results show that a maternal dose of 900 mg of
ω-3 LCPUFA per day during pregnancy had no effect on
symptoms of allergic disease or sensitization over time.
Long-term follow-up of perinatal interventions is critical
to evaluate effects which may manifest themselves only
after several years [29]. This is particularly important for
prenatal interventions aimed at primary prevention of aller-
gic disease in which the timing of onset, the nature of clin-
ical symptoms and sensitization to specific allergens is
known to be heterogeneous [30–33]. Longitudinal analysis
of multiple assessment throughout long-term follow-up is
the optimal method to determine effects over time. To
Fig. 2 Sensitization to one or more allergen extracts at 1, 3 and 6 years
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ensure consistency in outcome reporting we combined pre-
viously unpublished parent reported symptoms of allergic
disease (collected using ISAAC questionnaire) at 1 and
3 years of age with 6-year ISAAC data.
The progression in the prevalence of parent reported al-
lergic disease symptoms was consistent with the atopic
march and increased from 17.5% at 1 year of age to 49.3%
at 6 years of age. IgE mediated allergic disease symptoms
(symptoms and sensitization to ≥1 allergen extract) were re-
ported less often with 5.3% at 1 year of age increasing to
29.0% at 6 years of age, longitudinal analysis found no sig-
nificant differences between the ω-3 LCPUFA and control
groups over time. Our previous work has reported a signifi-
cant reduction in sensitization to egg at 1 year of age [17]
and HDM at 6 years of age [18] following maternal ω-3
LCPUFA supplementation, however our longitudinal
analysis did not show any age dependent effects. Our results
strongly support known associations between early
sensitization to food protein and later sensitization to
aero-allergens [34–36]. Prenatal ω-3 LCPUFA supplementa-
tion was observed to significantly decrease the risk of hen’s
egg sensitization at 1 year of age and HDM sensitization at
6 years of age with the association more pronounced in the
ω-3 LCPUFA group. There is growing evidence that
early-life sensitization to hen’s egg and sensitization to
HDM predict asthma and rhino-conjunctivitis in childhood
[37] adolescence [38] and adulthood [30]. We anticipated
that the reduction in HDM sensitization would be a
cascade effect of the effects of the intervention on
egg sensitization at 1-year of age, however, mediation
analysis to investigate sensitization associations,
showed that most of the effect of treatment on
Fig. 3 Sensitization to hen’s egg at 1, 3 and 6 years (*denotes p = < 0.05)
Fig. 4 Sensitization to peanut 1, 3 and 6 years
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HDM sensitization was unrelated to earlier effects
on egg sensitization (relative risk changing from 0.62
without adjustment, to 0.69 with adjustment).
The majority of RCTs designed to investigate the effect of
prenatal ω-3 LCPUFA supplementation on childhood al-
lergy have been driven by the plausible hypothesis that diets
high in ω-3 LCPUFAs may modulate the development of
immunoglobulin E (IgE) associated allergic disease [14–18,
23]. Whilst there is a level of consistency with reports of
protective effects of ω-3 LCPUFA on some sensitization
outcomes, a lack of congruence regarding effects on allergic
disease symptoms persist. Disparity in results between trials
may be attributed to several factors including, but not lim-
ited to; timing and dose of the intervention, type of inter-
vention (predominantly DHA vs. EPA), inconsistent
outcome reporting, the absence of long term follow-up of
outcomes and methodological issues. In regard to timing of
supplementation, post-natal supplementation alone (either
directly to the infant or via breastmilk) has not proved
beneficial in the reduction of allergic disease [13, 39]. Only
one trial has continued prenatal ω-3 LCPUFA supplementa-
tion throughout the post-natal period [14]. Whilst sample
size of this trial was small and offspring follow up was
ceased at 2 years of age, results suggest that continued sup-
plementation of breastfeeding mothers to compensate for
the natural decline in maternal plasma ω-3 LCPUFAs, may
provide additional benefit to the development and matur-
ation of the infant immune system. Compared with our
study, other studies have used much higher doses of ω-3
LCPUFA that have ranged from 2700 mg/day [14, 19–21]
to 3700 mg/day [16]. With benefit of the increasing evi-
dence in this field now available, we recognize that our dose
Fig. 5 Sensitization to cashew at 3 and 6 years
Fig. 6 Sensitization to D. farinae at 3 and 6 years (*denotes p = < 0.05)
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Fig. 7 Sensitization to cat at 1, 3 and 6 years
Table 3 Longitudinal analysis of sensitization to allergen extracts at 1, 3 and 6 years of age












Any Sensitization 1 50/349 (14.33%) 63/317 (19.87%) 0.72 (0.51, 1.01) 0.06 0.16 0.73 (0.52, 1.02) 0.07 0.10
3 77/303 (25.41%) 74/279 (26.52%) 0.96 (0.73, 1.26) 0.76 0.97 (0.74, 1.27) 0.83
6 124/248 (50.00%) 116/232 (50.00%) 1.00 (0.84, 1.20) > 0.99 1.05 (0.88, 1.25) 0.56
All years 0.94 (0.79, 1.12) 0.47 0.97 (0.82, 1.15) 0.76
Egg sensitization‡ 1 34/349 (9.74%) 51/317 (16.09%) 0.61 (0.40, 0.91) 0.02 0.55 0.62 (0.42, 0.93) 0.02 0.54
3 11/307 (3.58%) 15/280 (5.36%) 0.67 (0.31, 1.43) 0.30 0.68 (0.32, 1.44) 0.31
6 6/248 (2.42%) 5/232 (2.16%) 1.12 (0.35, 3.63) 0.85 1.16 (0.36, 3.73) 0.81
All years 0.65 (0.42, 1.01) 0.05 0.67 (0.43, 1.02) 0.06
Peanut sensitization 1 15/349 (4.30%) 22/317 (6.94%) 0.62 (0.33, 1.17) 0.14 0.98 0.65 (0.34, 1.22) 0.18 0.98
3 12/307 (3.91%) 18/280 (6.43%) 0.61 (0.30, 1.24) 0.17 0.63 (0.31, 1.27) 0.20
6 18/250 (7.20%) 29/232 (12.50%) 0.58 (0.33, 1.01) 0.05 0.61 (0.35, 1.06) 0.08
All years 0.60 (0.37, 0.98) 0.04 0.63 (0.39, 1.02) 0.06
Cat sensitization 1 7/349 (2.01%) 5/317 (1.58%) 1.27 (0.41, 3.97) 0.68 0.11 1.30 (0.42, 4.00) 0.65 0.12
3 24/303 (7.92%) 11/277 (3.97%) 1.99 (1.00, 4.00) 0.05 2.02 (1.02, 4.02) 0.04
6 30/247 (12.15%) 27/231 (11.69%) 1.04 (0.64, 1.69) 0.88 1.07 (0.66, 1.74) 0.79
All years 1.30 (0.80, 2.13) 0.29 1.34 (0.83, 2.18) 0.23
Cashew sensitization 3 5/307 (1.63%) 11/280 (3.93%) 0.41 (0.15, 1.18) 0.10 0.56 0.43 (0.15, 1.20) 0.11 0.50
6 9/249 (3.61%) 16/231 (6.93%) 0.52 (0.24, 1.16) 0.11 0.55 (0.25, 1.25) 0.15
All years 0.48 (0.21, 1.08) 0.08 0.50 (0.22, 1.14) 0.10
D. Farinae sensitization 3 16/303 (5.28%) 15/277 (5.42%) 0.98 (0.49, 1.94) 0.94 0.15 0.98 (0.50, 1.94) 0.96 0.18
6 31/246 (12.60%) 49/231 (21.21%) 0.59 (0.39, 0.90) 0.01 0.62 (0.41, 0.93) 0.02
All years 0.68 (0.46, 1.00) 0.05 0.70 (0.47, 1.03) 0.07
For ω-3 LCPUFA and control groups, data are number of subjects (percentage)
Longitudinal analysis not performed for sensitization to ryegrass, olive, D. pteronyssinus and alternaria tenuis due to insufficient cases at 1/3 years
Abbreviations: CI confidence interval, ω-3 LCPUFA long chain polyunsaturated fatty acid, RR relative risk
a bAdjusted for enrolling centre, parity, child sex and maternal history of allergic disease
Best et al. World Allergy Organization Journal  (2018) 11:10 Page 9 of 11
of ω-3 LCPUFA may not have been adequate and it may be,
that higher doses are needed to see a reduction in clinical
outcomes of allergic disease. However, we are also cognizant
of potential adverse effects of ω-3 LCPUFA supplementa-
tion as seen by the increased rate of obstetric interventions
in the arm of the DOMInO Trial due to an increase in
length of gestation in the intervention group [24].
To the best of our knowledge, this is the first longitu-
dinal analysis of sensitization and parent reported allergic
disease symptoms in the offspring following maternal ω-3
LCPUFA supplementation. The major strength of our
work is the use of data from the DOMInO Trial which
was primarily designed to investigate post-natal depres-
sion in women and neurodevelopment in children [24].
Long-term follow up of children from this well conducted
RCT with excellent follow up rates and a low risk of bias
has enabled a longitudinal analysis of allergic disease out-
comes that has not been possible in previous trials. Our
consistently collected outcome measures have enabled
combination of data from multiple time points into spe-
cific analyses that investigate change over time.
A limitation of this analysis may be the use of the ISAAC
questionnaire for the diagnosis of allergic disease symptoms,
particularly in infancy given that it has only been validated
for 6–7 and 13–14 year old children [40]. There were some
discrepancies between overall prevalence of allergic disease
diagnosis determined by parental reported symptoms from
ISAAC questionnaires at 1 and 3 years of age and physician
assessment. At 1 year of age, eczema with sensitization was
reported less often using ISAAC questionnaires compared
to physician diagnosis (3.5% vs. 9.2%) whilst at 3 years of
age, wheeze with sensitization was more frequently reported
by ISAAC questionnaires than physician diagnosed asthma
(11.6% vs. 1.6%). This difference in outcome measures high-
lights the complexity of using wheeze a proxy for asthma
diagnosis, particularly in children under pre-school age (<
6 years) when the many wheezing conditions of childhood
are prevalent. This disparity in outcome measures further
highlight the difficulties surrounding consistent methods for
allergic disease symptom definition and the importance of
standardization of core outcome reporting.
Conclusion
Although there is some evidence to suggest that maternal
supplementation with 900 mg ω-3 LCPUFA has a protect-
ive effect on early symptoms of allergic disease and
sensitization, we did not observe any differences in the pro-
gression of disease over time in this longitudinal analysis.
Further investigation into patterns of sensitization, classifi-
cation of atopy phenotypes and harmonization of clinical
symptom recording are essential to progress this field. Long
term follow-up of offspring (in adolescence and adulthood)
following prenatal interventions are essential to determine
true effects on the trajectory of disease and to confirm
whether prenatal ω-3 LCPUFA supplementation may be of
benefit as a primary prevention strategy.
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